TPU PHARMA
DEAD

Serial Number

87335893

Owner

Teikoku Pharma USA, Inc.

Attorney

Bret E. Field

Filing Date

Feb 14, 2017

Add to watchlist:

No watchlists yet
View on USPTO

TPU PHARMA Trademark

Serial Number: 87335893

TPU PHARMA is a trademark filed by Teikoku Pharma USA, Inc. on February 14, 2017. The trademark is classified under Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Teikoku Pharma USA, Inc. (38 trademarks)

1718 Rigwood Avenue
San Jose, CA 95131

Entity Type: 03

Trademark Details

Filing Date

February 14, 2017

Registration Date

Not Registered

Published for Opposition

September 5, 2017

Goods & Services

Pharmaceuticals for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; pharmaceutical preparations, compositions, creams and lotions for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations, namely, transdermal gel formulations, transdermal cream formulations, oral mucous formulations, transdermal patches, dressings and medical adhesive tapes for use in the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; pharmaceutical products, namely, analgesics

Cosmetics; cosmetic preparations; adhesives for cosmetic purposes; cosmetic masks; non-medicated soaps for personal use; perfumery; essential oils; hair lotions

Wholesale and retail store services and online wholesale and retail store services featuring pharmaceutical products and medical devices for storage, application and disposal of pharmaceutical preparations; Retail and wholesale store services and online retail and wholesale store services featuring pharmaceutical preparations, veterinary preparations, sanitary preparations, and medical supplies for storage, application and disposable of pharmaceutical preparations

Pharmaceutical research and development; pharmaceutical product evaluation, testing and inspection services; providing medical and scientific research information in the field of pharmaceuticals; information, advisory and consultancy services relating to pharmaceutical product evaluation, testing and inspection services

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 7, 2020 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 7, 2020 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 12, 2020 EXRA
SOU EXTENSION 5 GRANTED
May 11, 2020 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 11, 2020 AITU
SOU EXTENSION 5 FILED
Apr 24, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Apr 24, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 30, 2019 EXRA
SOU EXTENSION 4 GRANTED
Oct 28, 2019 EX4G
SOU EXTENSION 4 FILED
Oct 28, 2019 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 28, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 30, 2019 EXRA
SOU EXTENSION 3 GRANTED
Apr 26, 2019 EX3G
SOU EXTENSION 3 FILED
Apr 26, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 26, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 27, 2018 EXRA
SOU EXTENSION 2 GRANTED
Oct 25, 2018 EX2G
SOU EXTENSION 2 FILED
Oct 25, 2018 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 25, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 24, 2018 EXRA
SOU EXTENSION 1 GRANTED
Apr 20, 2018 EX1G
SOU EXTENSION 1 FILED
Apr 20, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 20, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 31, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 5, 2017 NPUB
PUBLISHED FOR OPPOSITION
Sep 5, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 16, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 26, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 26, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 26, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 26, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 26, 2017 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 20, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 19, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 19, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 24, 2017 GNRN
NON-FINAL ACTION E-MAILED
May 24, 2017 GNRT
NON-FINAL ACTION WRITTEN
May 24, 2017 CNRT
ASSIGNED TO EXAMINER
May 9, 2017 DOCK
NOTICE OF PSEUDO MARK E-MAILED
Feb 22, 2017 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 21, 2017 NWOS
NEW APPLICATION ENTERED
Feb 17, 2017 NWAP